Morning Briefing
Summaries of health policy coverage from major news organizations
Sales Of Hepatitis Drug Shatter Records
Record sales of the pricey new drug, Sovaldi, boosted first-quarter earnings of Gilead Sciences beyond expectations. Meanwhile, Novartis' recently announced deals with GlaxoSmithKline and Eli Lilly show manufacturers' swing towards specialization, reports The Wall Street Journal.
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
